FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Tasigna (nilotinib) submitted by Novartis, resulting in updated labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Tasigna (nilotinib)

Snippet

SUPPL AP for TASIGNA (NILOTINIB)